64x

About 64x

64x Bio is a startup that operates in the biotechnology industry, specifically in the cell and gene therapy sector. The company's primary focus is on the development and optimization of mammalian cell lines, which are crucial in the design and manufacture of next-generation therapeutics.

In simpler terms, 64x Bio uses advanced technology to engineer cells in a way that enhances their ability to produce new and improved treatments for various diseases. This process involves high throughput genome engineering and screening technologies, which essentially means they can manipulate and analyze a large number of cells quickly and efficiently.

The company's unique approach also incorporates computational tools in a design loop, allowing for a more streamlined and effective process. This innovative method enables the creation of cell lines that were previously unattainable, opening up new possibilities in the field of cell and gene therapy.

64x Bio's clients primarily include pharmaceutical and biotechnology companies, as well as Contract Development and Manufacturing Organizations (CDMOs). These organizations can leverage 64x Bio's platform technologies to bring cell and gene therapies to patients more effectively.

The business model of 64x Bio is likely based on providing its cell line engineering services to these companies, thus generating revenue. However, the company could also potentially earn income from licensing its technologies or through partnerships and collaborations in the biotech industry.